Business Wire

Regnology Completes Acquisition of Moody’s Regulatory Reporting & Asset and Liability Management (ALM) Solutions

5.5.2026 08:00:00 CEST | Business Wire | Press Release

Share

Regnology, a global provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the completion of its acquisition of Moody’s Regulatory Reporting & ALM Solutions business. The transaction expands Regnology’s solution portfolio with Moody’s comprehensive capabilities covering Basel III compliance, IFRS 9 impairment, large‑bank asset and liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting.

The transaction closes at a pivotal inflection point. Financial institutions face intensifying regulatory scrutiny, growing data complexity, and rising expectations for governance and auditability, while advances in artificial intelligence are creating new opportunities to modernize control frameworks and operating models. Regnology is responding by accelerating its Straight-Through Reporting (STR) vision and leveraging the combined capabilities of the transaction to deliver more resilient, transparent, and efficient frameworks across the regulatory, risk, and finance functions.

For clients transitioning from Moody’s, Regnology’s foremost commitment is to business continuity and service excellence, supported by a global team of more than 2,500 professionals, including over 1,000 dedicated regulatory, risk, and service specialists.

Rob Mackay, Chief Executive Officer of Regnology said: “The completion of this transaction is a powerful catalyst for advancing our ambition to build the compliance operating system of the future and to break down traditional silos between Chief Risk Officers and Chief Financial Officers. By combining expanded functional coverage with deep regulatory expertise and modern, governed technology, we are uniquely positioned to help institutions strengthen control frameworks, increase transparency, and turn compliance into a source of insight and confidence.”

The combined solutions will strengthen and extend Regnology’s existing best‑of‑breed solution lines, including Regnology Reporting Hub (RRH), Regnology Risk Hub (RRiH), and Regnology Finance Hub (RFH), enhancing coverage across regulatory reporting, finance, risk, capital, liquidity, and ALM. As these solution lines are progressively onboarded onto Ascend, Regnology’s next‑generation, modular, cloud‑native platform, they will benefit from the platform’s shared services, scale and operational resilience, while retaining their domain‑specific strengths.

This approach builds on Regnology’s proven, battle-tested ability to deliver transformation at scale while preserving continuity. The recently introduced RGI governed intelligence layer further strengthens Ascend by enabling a scalable, governed environment where data, intelligence, and workflows converge, reducing fragmentation and manual intervention across the regulatory lifecycle.

Looking ahead, Regnology will continue to invest in talent, platform innovation, and AI to meet the evolving regulatory demands of global financial markets.

About Regnology

Regnology is a recognized leader in regulatory, risk, tax, and finance reporting technology— connecting regulators and the regulated across more than 100 countries. Our unique position enables us to span the full spectrum of industry needs, delivering solutions that address both oversight and compliance requirements to a broad range of clients, including global Tier 1 banks, local and regional institutions, corporates, insurers, and authorities.

With presence in over 30 countries and deep local expertise, Regnology combines a truly global approach with an understanding of regional regulatory requirements. Our unified data model and “map once, report many” methodology ensure consistency, auditability, and scalability across jurisdictions, while our modular, cloud-native solutions empower clients to achieve compliance, unlock enterprise-wide insights, and future-proof their operations.

Regnology’s leadership is underpinned by fast-paced growth and a front-running approach to innovation, continually investing in automation, AI, and domain expertise to deliver future-ready solutions.

For more information about Regnology, connect with us on LinkedIn.

Visit our website: www.regnology.net.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260504135988/en/

Contacts

Mireille Adebiyi – Chief Marketing Officer
Email: mireille.adebiyi@regnology.net

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SES’s O3b mPOWER Satellite Network to Connect Seven New Petrobras FPSOs5.5.2026 08:50:00 CEST | Press Release

SES, a leading space solutions company, will provide service on its high-capacity medium-Earth orbit (MEO) satellite network, O3b mPOWER, to Petrobras, the Brazilian state-owned oil company, to connect multiple new Floating Production, Storage and Offloading systems (FPSOs). The projects will go into operation in the coming years, expanding Petrobras’ oil and gas production capacity to meet national energy needs and contribute to global oil markets. FPSOs are modern and efficient oil production platforms, responsible for processing, collecting, storing, and transferring oil to shuttle tankers, directly from subsea wells in deepwater fields. FPSOs offer the flexibility, capacity, and operational resilience needed to sustain large-scale offshore production in remote and challenging environments. Brazil is home to the majority of the offshore projects under development worldwide, and Petrobras is one of the largest FPSO operators on the planet, responsible for most of the country’s oil an

AB InBev Reports First Quarter 2026 Results5.5.2026 07:02:00 CEST | Press Release

Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504526109/en/ Regulated information1 “Cheers to beer - the strength of the category and the consistent execution of our consumer-centric strategy drove continued momentum across our footprint. We are investing behind our megabrands and innovations to lead and grow the category. With strong execution by our teams and major moments of celebration ahead, we are well positioned for 2026.” – Michel Doukeris, CEO, AB InBev Revenue +5.8% Revenue increased by 5.8% with revenue per hl growth of 4.5%. Reported revenue increased by 12.0% to 15 267 million USD, positively impacted by currency translation. 8.2% increase in combined revenues of megabrands, led by Corona, which grew by 16% outside of its home market. 27% increase in revenue of no-alcohol beer. 37% increase in revenue of Beyond Beer. 55% increase in Gross Mer

Kerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 20264.5.2026 20:25:00 CEST | Press Release

Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at the EWMA‑DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504487743/en/ MariCell® Solid This year, The European Wound Management Association's (EWMA) meeting is held in conjunction with the Deutscher Wundkongress (DEWU); combining two major wound-care congresses into a single forum for scientific exchange, education, and clinical discussion. At this year’s conference, Kerecis will highlight growing clinical experience with intact fish‑skin grafts across a broad range of wound indications, supported by two Kerecis‑led scientific symposia, multiple oral and poster presentations, and direct engagement with clinicians at Booth D30, located adjacent

Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit4.5.2026 20:00:00 CEST | Press Release

CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today officially announces the launch of its North American subsidiary, CTIBIOTECH USA™. The official launch took place today at the prestigious SelectUSA Investment Summit in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504107996/en/ From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine Operating from its new United States base in the thriving life sciences “Cellicon Valley” hub of Philadelphia, Pennsylvania, in association with BioLabs for Advanced Therapeutics, CTIBIOTECH USA™ will provide the company's proprietary human cell and tissue bioassays and New Approach Methods (NAMs) directly to North American pharmaceutical, biomedical, and dermatocosmetics markets. By producing and supplying these cutting-edge human bioassays domesti

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press Release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye